

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Lizare and The material base have licensed to an am

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Section 1.											
Identifying Information											
Given Name (First Name) David		2. Surnar Schwartz	ne (Last Nam Z	ne)	3. Date 25-January-2018						
4. Are you the co	Yes	✓ No	·	Corresponding Author's Name Prof Philippe Dieude							
5. Manuscript Titl MUC5B promote	e er variant rs35705950 is	s a risk facto	or for rheun	natoid arthritis -	interstitia	ıl lung disease					
6. Manuscript Ide	ntifying Number (if you k	now it)									
Section 2.	The Work Under C	onsiderat	ion for Pu	ublication							
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No											
If yes, please fill out the appropriate information below. If you have more than one entity press the "ADD" button to add a row. Excess rows can be removed by pressing the "X" button.											
Name of Institu	tion/Company	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments					
NIH-NHLBI		✓				P01 HL092870					
IIH-NHLBI		✓				R01 HL097163					
NIH-NHLBI		✓				R33 HL120770					
IIH-NHLBI		✓				UH2 HL123442					
OOD Focused Program Grant		✓				W81XWH-17-1-0597					
Section 3.	Relevant financial	activities	outside t	he submitted	work.						
of compensation	n) with entities as descr	ibed in the	instruction	is. Use one line fo	or each ei	cial relationships (regardless of amount ntity; add as many lines as you need by e 36 months prior to publication.					
•	levant conflicts of inter out the appropriate inf			No							



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments
leven P15, Inc.				✓	Employee of company with mission of early detection and early intervention of IPF
luMedii, Inc.		✓			Consultant on Pulmonary Fibrosis Advisory Board
Section 4. Intellectual Prope	rty Pate	ents & Cop	oyrights		
Do you have any patents, whether plan	ned, pend	ng or issue	ed, broadly releva	nt to the	work? 🗸 Yes 🗌 No
If yes, please fill out the appropriate inf Excess rows can be removed by pressin			u have more than	one enti	ty press the "ADD" button to add a
Patent? Pendi	ng? Issue	d? Licens	ed?Royalties?	License	ce? Comments
ompositions and Methods of reating or Preventing Fibrotic iseases					62/525,088 submitted 6/26/17
iomarkers for the diagnosis and eatment of fibrotic lung disease					62/525,087; submitted 6/26/17
lethods and Compositions for Risk rediction, Diagnosis, Prognosis, and reatment of Pulmonary Disorders	√				US Patent serial no: 8,673,565; awarded March 18, 2014
Section 5. Relationships not	covered	ahove			
Are there other relationships or activitic potentially influencing, what you wrote	es that read	lers could _l		influence	d, or that give the appearance of
Yes, the following relationships/cor					
At the time of manuscript acceptance, j On occasion, journals may ask authors					



Section 6.

Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Schwartz reports grants from NIH-NHLBI, grants from DOD Focused Program Grant, during the conduct of the study; other from Eleven P15, Inc., personal fees from NuMedii, Inc., outside the submitted work; In addition, Dr. Schwartz has a patent Compositions and Methods of Treating or Preventing Fibrotic Diseases pending, a patent Biomarkers for the diagnosis and treatment of fibrotic lung disease pending, and a patent Methods and Compositions for Risk Prediction, Diagnosis, Prognosis, and Treatment of Pulmonary Disorders issued.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.